Search
# Popular search #
# Popular search #
Founded R&D Center - Beijing Gan & Lee Biotechnology Co., Ltd. (later became Gan & Lee Pharmaceuticals)
Completed the construction of the world's 3rd largest recombinant human insulin production base
Successfully developed China's 1st fast-acting human insulin analog - Prandilin® (Lispro)
Successfully developed China's 1st long-acting human insulin analog - Basalin® (Glargine)
Successfully developed China's 1st premixed human insulin analog - Prandilin ® 25 (Lispro 25R)
Company was restructured and renamed to“Gan & Lee Pharmaceuticals Co., Ltd.”
Patents were obtained for the Molecular Chaperone Technology in China and PCT patent was obtained in the US
Received production approval and GMP certificate for Basalin® from the NMPA (before CFDA)
Basalin® went on sale
Basalin® entered the international market, including Egypt, Pakistan, Mexico, etc.
The company's sales revenue exceeded RMB100 million
China's 1st independently developed insulin injection pen-Insulin Pen was launched
The company completed the shareholding transformation and its name was changed to “Gan & Lee Pharmaceuticals”
China's 1st premixed human insulin analog Prandilin® 25 was launched
Founded Gan & Lee Pharmaceuticals USA
Completed the construction of the new insulin analog manufacturing plant in Beijing
Insulin glargine was allowed by the FDA to proceed with Phase I clinical study in US
Basalin passed Europe's QP inspection and was allowed to proceed with Phase I and Phase III clinical trials in Europe
Gan & Lee attended the 78th American Diabetes Annual Conference (ADA) as the first Chinese pharmaceuticals to attend the conference
Gan & Lee concluded a commercialization and supply agreement with Sandoz, a subsidiary of Novartis on biosimilar versions of insulins used in patients with type 1 and type 2 diabetes
Recombinant insulin lispro was allowed by the FDA & European Medicines Agency to proceed with Phase I and Phase III clinical trials in the US and Europe
Gan & Lee was Initially listed on the A-share index on the Shanghai Stock Exchange
Aspart was approved for listing in China
Started the construction of Gan & Lee Linyi Production Base
Phase 1 Drug Candidate GLR2007 has been Granted Orphan Drug Designation and Fast Track Designation by the US FDA
Gan & Lee Announces New Partnership with the International Diabetes Federation
EMA granted orphan drug designation for GLR2007
Mixed Protamine Human Insulin Injection (30R) from Gan & Lee Pharmaceuticals is listed
GZR18, a GLP-1 RA, began the phase I clinical trial in China and the US.
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.